Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06732492CT.gov RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoid Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| rd13-02 cell infusion (this asset) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P1 | CC · 43 |
| Cyclophosphamide | Case Comprehensive Cancer Center | P2 | BB |
| Etoposide | M.D. Anderson Cancer Center | P2 | BB |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Abt-263 | AbbVie | P1/2 | B |
| Fludarabine | M.D. Anderson Cancer Center | P2 | B |
| Nivestim | M.D. Anderson Cancer Center | P2 | B |
| Bortezomib | M.D. Anderson Cancer Center | P2 | B |
| Camustine | M.D. Anderson Cancer Center | P2 | B |
+24 more in the Lymphoid Neoplasm cohort
Other indications for rd13-02 cell infusion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hematopoietic And Lymphoid System Neoplasm | — | Early P1 | CCC · 48 |
| Hematologic Disorder | — | Early P1 | CC · 47 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. rd13-02 cell infusion in Lymphoid Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rd13-02-cell-infusion-lymphoid-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →